search
Back to results

The Effects of Sodium and Potassium on Blood Pressure, Vascular Function and Renal Function (KaNa)

Primary Purpose

Hypertension, Blood Pressure, Vascular Function

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Sodium
Potassium
Placebo
Sponsored by
Wageningen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Hypertension focused on measuring sodium, salt, potassium, blood pressure, flow-mediated dilatation, endothelial function, renal function, controlled feeding study, dietary intervention

Eligibility Criteria

40 Years - 90 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • (Pre)hypertension, defined as office SBP: 130-159 mmHg;
  • No use of antihypertensive, lipid-lowering, anticoagulant or other cardiovascular medication;
  • Age at start of the ≥ 40 years;
  • Apparently healthy:

    • No reported current or previous metabolic diseases
    • No history of cardiovascular diseases
    • No history of renal, liver or thyroid diseases
    • No history of gastrointestinal diseases
    • No diabetes mellitus
    • Fasting laboratory parameters within normal range: renal function (serum creatinine, ureum), liver function (ALAT, ASAT, ɣ-GT) and serum glucose.

Exclusion Criteria:

  • Body mass index > 40 kg/m²;
  • Smoking
  • Secondary hypertension;
  • Weight loss or weight gain of 5 kg or more during the last 2 months;
  • Usage of non-steroidal anti-inflammatory drugs (aspirin, ibuprofen, naproxen) and not able or willing to stop taking them from at least 4 weeks prior to the study.
  • Medical treatment that may affect blood pressure and not able (or willing) to stop taking them;
  • Women taking oral contraceptives or estrogen replacement therapy
  • Taking nutritional supplements and unwilling to discontinue;
  • Women lactating, pregnant or intend to become pregnant during study;
  • Reported dietary habits: medically prescribed diet, slimming diet;
  • Reported alcohol consumption > 21 units/w (female subjects) or >28 units/w (male subjects);
  • Unable or unwilling to consume one meal every workday at the university, or to consume the prescribed study diet for 13 weeks;
  • Problems with consuming the supplements or following the study guidelines;
  • Unwilling to undergo home or office blood pressure measurements;
  • Recent blood donation i.e. 1 month (male subjects) or 2 months (female subjects) prior to the study and planned donation during the study period;
  • Reported intense sporting activities > 10 h/w;
  • Not agreeing to be informed about unexpected and medically relevant personal test-results
  • Participation in another biomedical trial less than 2 months before the start of the study or at the same time;
  • No informed consent signed.

Sites / Locations

  • Wageningen University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Placebo Comparator

Arm Label

Sodium

Potassium

Placebo

Arm Description

For 4 weeks subjects will consume 3 grams of sodium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet

For 4 weeks subjects will consume 3 grams of potassium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet.

For 4 weeks subjects will consume placebo capsules (content: cellulose) on top of a low-sodium low-potassium diet

Outcomes

Primary Outcome Measures

Change in Endothelium-dependent flow-mediated dilation comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Ultra-sonography (brachial artery) + Picus system

Secondary Outcome Measures

Change in blood pressure comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Includes: Office BP (Dinamap, 4 consecutive measurements with 2-min intervals) ABPM (Spacelab; 1x24h, at baseline, week 5, week 9, week 13)
Change in Pulse Wave Velocity comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Device: SphygmoCor (tonometry) Parameters: Pulse Wave Velocity and at baseline, week 5, week 9 and week 13
Change in vasomotion comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Device: PeriFlux 5000 (Perimed, Sweden0
Change in Biomarkers of endothelial function comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Plasma analysis of endothelin-1, ADMA, MCP-1, sVCAM-1, sICAM-1, sE-selectin, sTM, CRP, SAA, IL-6, IL-8, TNF-α, vWF, nitric oxide
Change in renal function comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
eGFR, serum creatinine (at screening also used as safety parameter)
Change in cardiovascular parameters in plasma comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, insulin and glucose (at screening also used as safety parameter)
Liver function parameters
Montoring liver function parameters for safety: includes ALAT, ASAT and ɣ-GT
24-hour urinary mineral excretions
Sodium and potassium (as compliance markers)
24-hour excretion of protein, albumin and creatinine
In addition, protein is assessed in spot urine during screening using a dipstick test
Adverse events
Patient diary for occasions of illness, hospitalizations, medication use and other information on potential side effects
Anthropometric measurements
Body weight (weekly), height (only at baseline), waist circumference (baseline and every 4 weeks)
Heart rate
Dinamap, 4 consecutive measurements with 2-min intervals
Food frequency questionnaire
Change in Pulse Wave Analysis comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Device: SphygmoCor (tonometry)

Full Information

First Posted
March 20, 2012
Last Updated
August 9, 2012
Sponsor
Wageningen University
Collaborators
Top Institute Food and Nutrition
search

1. Study Identification

Unique Protocol Identification Number
NCT01575041
Brief Title
The Effects of Sodium and Potassium on Blood Pressure, Vascular Function and Renal Function
Acronym
KaNa
Official Title
Study on the Effects of Sodium and Potassium on Blood Pressure, Vascular Function and Renal Function in Untreated (Pre)Hypertensive Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
August 2012
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
July 2012 (Actual)
Study Completion Date
August 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wageningen University
Collaborators
Top Institute Food and Nutrition

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To determine the effect of (1) increased sodium intake and (2) increased potassium intake on blood pressure, vascular function and renal function in untreated (pre)hypertensive subjects.
Detailed Description
This is a randomized, double-blind, placebo controlled cross-over feeding study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Blood Pressure, Vascular Function, Renal Function
Keywords
sodium, salt, potassium, blood pressure, flow-mediated dilatation, endothelial function, renal function, controlled feeding study, dietary intervention

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sodium
Arm Type
Active Comparator
Arm Description
For 4 weeks subjects will consume 3 grams of sodium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet
Arm Title
Potassium
Arm Type
Active Comparator
Arm Description
For 4 weeks subjects will consume 3 grams of potassium by the intake of capsules on top of a low-sodium (2 grams of sodium), low-potassium (2 grams of potassium) diet.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
For 4 weeks subjects will consume placebo capsules (content: cellulose) on top of a low-sodium low-potassium diet
Intervention Type
Dietary Supplement
Intervention Name(s)
Sodium
Intervention Description
Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
Intervention Type
Drug
Intervention Name(s)
Potassium
Intervention Description
Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
Primary Outcome Measure Information:
Title
Change in Endothelium-dependent flow-mediated dilation comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Description
Ultra-sonography (brachial artery) + Picus system
Time Frame
Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Secondary Outcome Measure Information:
Title
Change in blood pressure comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Description
Includes: Office BP (Dinamap, 4 consecutive measurements with 2-min intervals) ABPM (Spacelab; 1x24h, at baseline, week 5, week 9, week 13)
Time Frame
Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Title
Change in Pulse Wave Velocity comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Description
Device: SphygmoCor (tonometry) Parameters: Pulse Wave Velocity and at baseline, week 5, week 9 and week 13
Time Frame
Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Title
Change in vasomotion comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Description
Device: PeriFlux 5000 (Perimed, Sweden0
Time Frame
Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Title
Change in Biomarkers of endothelial function comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Description
Plasma analysis of endothelin-1, ADMA, MCP-1, sVCAM-1, sICAM-1, sE-selectin, sTM, CRP, SAA, IL-6, IL-8, TNF-α, vWF, nitric oxide
Time Frame
Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Title
Change in renal function comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Description
eGFR, serum creatinine (at screening also used as safety parameter)
Time Frame
Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Title
Change in cardiovascular parameters in plasma comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Description
Total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, insulin and glucose (at screening also used as safety parameter)
Time Frame
Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Title
Liver function parameters
Description
Montoring liver function parameters for safety: includes ALAT, ASAT and ɣ-GT
Time Frame
Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Title
24-hour urinary mineral excretions
Description
Sodium and potassium (as compliance markers)
Time Frame
Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Title
24-hour excretion of protein, albumin and creatinine
Description
In addition, protein is assessed in spot urine during screening using a dipstick test
Time Frame
Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Title
Adverse events
Description
Patient diary for occasions of illness, hospitalizations, medication use and other information on potential side effects
Time Frame
Every day
Title
Anthropometric measurements
Description
Body weight (weekly), height (only at baseline), waist circumference (baseline and every 4 weeks)
Time Frame
Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Title
Heart rate
Description
Dinamap, 4 consecutive measurements with 2-min intervals
Time Frame
Screening. Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)
Title
Food frequency questionnaire
Time Frame
Screening
Title
Change in Pulse Wave Analysis comparing (1) high sodium, low potassium intake and (2) low sodium, high potassium intake with low sodium, low potassium intake.
Description
Device: SphygmoCor (tonometry)
Time Frame
Baseline at week 1 (t=0). After intervention period 1 at week 5 (t=1). After intervention period 2 at week 9 (t=2). After intervention period 3 at week 13 (t=3)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: (Pre)hypertension, defined as office SBP: 130-159 mmHg; No use of antihypertensive, lipid-lowering, anticoagulant or other cardiovascular medication; Age at start of the ≥ 40 years; Apparently healthy: No reported current or previous metabolic diseases No history of cardiovascular diseases No history of renal, liver or thyroid diseases No history of gastrointestinal diseases No diabetes mellitus Fasting laboratory parameters within normal range: renal function (serum creatinine, ureum), liver function (ALAT, ASAT, ɣ-GT) and serum glucose. Exclusion Criteria: Body mass index > 40 kg/m²; Smoking Secondary hypertension; Weight loss or weight gain of 5 kg or more during the last 2 months; Usage of non-steroidal anti-inflammatory drugs (aspirin, ibuprofen, naproxen) and not able or willing to stop taking them from at least 4 weeks prior to the study. Medical treatment that may affect blood pressure and not able (or willing) to stop taking them; Women taking oral contraceptives or estrogen replacement therapy Taking nutritional supplements and unwilling to discontinue; Women lactating, pregnant or intend to become pregnant during study; Reported dietary habits: medically prescribed diet, slimming diet; Reported alcohol consumption > 21 units/w (female subjects) or >28 units/w (male subjects); Unable or unwilling to consume one meal every workday at the university, or to consume the prescribed study diet for 13 weeks; Problems with consuming the supplements or following the study guidelines; Unwilling to undergo home or office blood pressure measurements; Recent blood donation i.e. 1 month (male subjects) or 2 months (female subjects) prior to the study and planned donation during the study period; Reported intense sporting activities > 10 h/w; Not agreeing to be informed about unexpected and medically relevant personal test-results Participation in another biomedical trial less than 2 months before the start of the study or at the same time; No informed consent signed.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Johanna M Geleijnse, PhD
Organizational Affiliation
Wageningen University, Division of Human Nutrition
Official's Role
Principal Investigator
Facility Information:
Facility Name
Wageningen University
City
Wageningen
ZIP/Postal Code
6703 HD
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
32506135
Citation
Humalda JK, Yeung SMH, Geleijnse JM, Gijsbers L, Riphagen IJ, Hoorn EJ, Rotmans JI, Vogt L, Navis G, Bakker SJL, de Borst MH. Effects of Potassium or Sodium Supplementation on Mineral Homeostasis: A Controlled Dietary Intervention Study. J Clin Endocrinol Metab. 2020 Sep 1;105(9):e3246-56. doi: 10.1210/clinem/dgaa359.
Results Reference
derived
Links:
URL
http://www.hne.wur.nl/UK
Description
Website of Division of Human Nutrition, Wageningen University, The Netherlands
URL
http://www.tifn.nl
Description
Website of the Top Institute Food and Nutrition, Wageningen, The Netherlands

Learn more about this trial

The Effects of Sodium and Potassium on Blood Pressure, Vascular Function and Renal Function

We'll reach out to this number within 24 hrs